Synthego Introduces First CRISPR Guaranteed Editing Genome Engineering Solution
December 14, 2017 09:02 ET
|
Synthego
REDWOOD CITY, Calif., Dec. 14, 2017 (GLOBE NEWSWIRE) -- Synthego, a leading provider of genome engineering solutions, announces the launch of its new CRISPRevolution™ Gene Knockout Kit (GKO) with...
CRISPR Therapeutics Announces Collaboration with Massachusetts General Hospital to Research Use of CRISPR/Cas9 in T Cell Cancer Therapies
August 22, 2017 07:30 ET
|
CRISPR Therapeutics AG
ZUG, Switzerland and CAMBRIDGE, Mass., Aug. 22, 2017 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ:CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for...
Taconic Biosciences Announces Partnership With Cergentis B.V. to Provide Transgene Mapping Services
August 14, 2017 09:00 ET
|
Taconic Biosciences
HUDSON, N.Y., Aug. 14, 2017 (GLOBE NEWSWIRE) -- Taconic Biosciences, a global leader in genetically engineered mouse models and associated services, announced it has signed a collaborative agreement...
Taconic Biosciences Announces Partnership With Cergentis B.V. to Provide Transgene Mapping Services
August 08, 2017 16:43 ET
|
Taconic Biosciences
HUDSON, N.Y., Aug. 08, 2017 (GLOBE NEWSWIRE) -- Taconic Biosciences, a global leader in genetically engineered mouse models and associated services, announced it has signed a collaborative agreement...
CRISPR Therapeutics Announces European Patent for CRISPR/Cas Gene Editing
March 28, 2017 08:00 ET
|
CRISPR Therapeutics AG
- Patent to include CRISPR/Cas9 gene editing compositions for use in any non-cellular and cellular setting, including human and other eukaryotic cells BASEL, Switzerland, March 28, 2017 (GLOBE...
CRISPR Therapeutics Announces the Appointment of Jon Terrett, Ph.D. to Head of Immuno-Oncology Research and Translation
February 28, 2017 08:00 ET
|
CRISPR Therapeutics AG
Experienced leader with extensive experience in immuno-oncologyDedicated unit in immuno-oncology to accelerate efforts BASEL, Switzerland and CAMBRIDGE, Mass., Feb. 28, 2017 (GLOBE NEWSWIRE) --...
CRISPR Therapeutics, Intellia Therapeutics, Caribou Biosciences and ERS Genomics Announce Global Agreement on the Foundational Intellectual Property for CRISPR/Cas9 Gene Editing Technology
December 16, 2016 08:00 ET
|
CRISPR Therapeutics AG
BASEL, Switzerland, CAMBRIDGE, Mass., BERKELEY, Calif. and DUBLIN, Ireland, Dec. 16, 2016 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ:CRSP), Intellia Therapeutics (NASDAQ:NTLA), Caribou...
CRISPR Therapeutics to Present at the Stifel 2016 Healthcare Conference
November 08, 2016 08:00 ET
|
CRISPR Therapeutics AG
BASEL, Switzerland and CAMBRIDGE, Mass., Nov. 08, 2016 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ:CRSP), a biopharmaceutical company focused on translating CRISPR-Cas9 gene-editing technology...
CRISPR Therapeutics Announces Pricing of Initial Public Offering
October 18, 2016 21:59 ET
|
CRISPR Therapeutics AG
BASEL, Switzerland and CAMBRIDGE, Mass., Oct. 18, 2016 (GLOBE NEWSWIRE) -- CRISPR Therapeutics AG (Nasdaq:CRSP), a biopharmaceutical company focused on translating CRISPR/Cas9 gene-editing...
Poseida Therapeutics Establishes Scientific Advisory Board
September 08, 2016 07:30 ET
|
Poseida Therapeutics, Inc.
SAN DIEGO, Sept. 08, 2016 (GLOBE NEWSWIRE) -- Poseida Therapeutics, Inc. (“Poseida”), a San Diego-based company translating best-in-class gene editing technologies into lifesaving therapeutics,...